Three researchers, working within the same hospital system, were studying related ways to interrupt fibrosis. They did not realize how much their work had in common. Meredith Fisher, a partner at Mass General Brigham Ventures, noticed. She brought their programs together. The result was Mediar Therapeutics: a company built around the possibility that the machinery producing scar tissue could itself become a target.
- Three antibodies target signals involved in scar formation.
- Lung and systemic sclerosis programs have reached Phase 2.
- Lilly licensed the lung program; Mediar retains its other two clinical assets.
- Stopping or reversing fibrosis remains a hypothesis under clinical examination.
Three labs had the same suspicion
The hospital venture team’s account describes investigators who saw greater strength in joining forces. Fisher helped finance the company and served as interim CEO. Paul Yaworsky became its first employee after financing. The interesting move was organizational: gather complementary experiments under one roof before asking any single experiment to carry an entire business.
Launched in 2019, Mediar subsequently recruited Rahul Ballal as CEO. Its scientific roots run through Massachusetts General and Brigham and Women’s hospitals. Today the Boston biotech is conducting human studies, converting a shared suspicion into three separate opportunities to be proved right or wrong.
The repair crew that stays too long
A scar is evidence that the body has been busy. The trouble begins when repair keeps going. Myofibroblasts deposit collagen and other extracellular material; in fibrosis, their activity can sustain an environment that damages an organ’s ability to function. Mediar’s question is whether neutralizing signals involved in that process can quiet the cells responsible.
This gives the company a different point of attack from approaches centered on the initiating immune response. Its antibodies are designed to interrupt fibrotic mediators. The distinction concerns where to intervene in disease biology. It does not establish that Mediar’s medicines will work better, or that existing approaches address only symptoms.
The three clinical candidates divide the work. MTX-463 targets WISP1 in idiopathic pulmonary fibrosis, or IPF. MTX-474 targets EphrinB2 in systemic sclerosis. MTX-439 targets SMOC2 in kidney fibrosis. All use an antibody format; the novelty lies in the targets and the therapeutic proposition.
Development stages indicate progress through testing, not demonstrated efficacy.
The numbers need their own microscope
In March 2023, Mediar announced $105 million in financing. The arithmetic matters: $85 million was the Series A, with $20 million from earlier funding. Novartis Venture Fund and Sofinnova Partners co-led the round. Pfizer, Lilly and Bristol Myers Squibb were among the participants. A syndicate can express conviction; it cannot substitute for a controlled trial.
Lilly then took a more direct position. The January 2025 global license for MTX-463 specified $99 million in combined upfront and near-term milestone payments. Up to $687 million more depends on downstream development and commercialization milestones. Potential royalties add another conditional layer. Describing the entire package as money already received would require remarkably accommodating arithmetic.
Mediar conducts the lung program’s Phase 2 study; Lilly has the right to lead further development and commercialization afterward. Mediar keeps MTX-474 and MTX-439. Its $76 million Series B, announced in January 2026 and co-led by Amplitude Ventures and ICG, supports those wholly owned assets.
In August 2026, Ono became a discovery partner, paying upfront and supporting research costs in exchange for an exclusive worldwide licensing option. Its venture arm had invested in 2021. Mediar’s business is therefore a mixture of financed research and pharmaceutical partnering, with future product economics tied to development success.
That expertise also has suppliers. In February 2026, Alloy Therapeutics reported that an antibody discovery collaboration moved candidates into downstream development six months earlier than expected. Alloy described selecting antibodies with target selectivity, cross-species reactivity and suitable development properties. The report is a useful reminder that finding an antibody is only part of the job. A candidate must also be practical to develop. The six-month figure is the partner’s reported comparison with its expected schedule, rather than evidence that a medicine will arrive six months sooner.
A blood signal is only the beginning
Mediar emphasizes targets that can be measured in blood and linked to disease severity. That makes a biological argument easier to examine. A drug can meet its intended target, however, without producing a meaningful clinical benefit. The patient’s lungs or skin must eventually have something to say.
The lung trial, WISPer, began patient dosing in 2025. Its primary endpoint measures change in forced vital capacity at 24 weeks. EncompaSSc, the systemic sclerosis study, plans approximately 90 participants and uses the modified Rodnan Skin Score as its primary endpoint. Both are randomized, double-blind and placebo-controlled. The names indulge in wordplay; the designs ask concrete questions.
The kidney program entered Phase 1 in 2026, examining safety, tolerability and pharmacokinetics in healthy volunteers and adults with diabetic kidney disease. It is earlier in the evidentiary journey. Meanwhile, the IPF treatment market includes nintedanib, pirfenidone and nerandomilast. Mediar’s candidates must earn their place alongside an evolving standard of care.
“Patients are at the heart of everything that we do.”Paul Yaworsky · Mediar’s values video
Borrow the question, then build the test
The useful lesson is a way of arranging uncertainty. Find related work that has been separated by institutional habits. Choose a mechanism that can be measured. Recruit expertise beyond the founding laboratory. Mediar’s leadership combines antibody engineering and clinical development; its stated culture prizes teamwork, inclusion and integrity. Those commitments belong to the company’s own account, rather than an independent verdict on office life.
The approach still depends on the targeted signals mattering enough in human disease, and on blocking them safely. My reading is that Mediar has made its central idea testable. That is an achievement in experimental design; a treatment benefit requires the experiments to deliver.
For patients, the practical route is clinical research. Mediar’s candidates are investigational. The WISPer website describes eight visits over up to 32 weeks, with study-related care at no cost and possible compensation for time and travel. Eligibility comes through the research team. A company born by connecting laboratories now needs another kind of connection: between a measurable signal and a patient who actually feels its consequence.